Special Issue "Proteins and Peptides as a Treatment for Cardiovascular Disease: From Bacteria to Human"
Deadline for manuscript submissions: 30 November 2023 | Viewed by 4988
Interests: cardiovascular diseases; heat shock proteins; antioxidants; immunomodulation; vaccines; inflammation; nanotoxicology; oxidative stress; cell signaling, therapeutics; proteins; peptides; exosomes.
Cardiovascular diseases that conclude with the pathological hypertrophy of the heart continue to be an important factor contributing to the progression toward the final stage of heart failure, where current treatments and interventions are not effective enough to reduce mortality. Even though cell injury and pathological hypertrophy are the culmination of the constant activation and accumulation of different pathways and stress responses, pathogens or self-proteins and peptides seem to play an important role in triggering the initial steps of unwanted progression toward these maladaptive events with the ultimate production of pro-hypertrophy and pro-inflammatory markers.
Protein and peptide dysregulation is well documented in processes such as metabolic diseases, obesity, atherosclerosis, diabetes mellitus, heart failure or even other pathologies, like cancer. Nevertheless, the role of these molecules as major mediators of cell, and tissue injury/damage needs to be studied in depth. Pathogen proteins or autologous proteins/peptides can act as strong modulators, with beneficial therapeutic values for their potential use as candidate targets in heart, kidney or lung by autocrine-, paracrine-, endocrine-, and pathogen-induced diseases. This Special Issue aims to explore the uses of proteins and peptides in silico, in vitro, and in vivo as novel therapeutic tools in the development of potent cell modulators or immunomodulators to block pathogens or to enhance protection against self-dysregulated mechanisms related to the development of cardiovascular diseases. We invite you to submit original works, research papers, reviews, and short communications.
Dr. Guerrero-Beltrán Enrique
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cardiovascular diseases
- proteins and peptides
- bioactive proteins and peptides
- therapeutic proteins and peptides
- pathogen and antimicrobial proteins
- anti-inflammatory proteins
- protein and peptide immunomodulation
- in silico, in vitro, and in vivo protein approach